<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752687</url>
  </required_header>
  <id_info>
    <org_study_id>M10-573</org_study_id>
    <nct_id>NCT00752687</nct_id>
  </id_info>
  <brief_title>A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers
      and its anti-viral activity in HCV infected subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A blinded, randomized, placebo-controlled trial to study the safety, tolerability, antiviral
      activity and pharmacokinetic profiles of ABT-072 in healthy and HCV genotype-1 infected
      adults.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of pharmacokinetic variables and mean change in HCV RNA level from baseline.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-072</intervention_name>
    <description>Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Criteria for Healthy Adults:

          -  Informed consent has been obtained

          -  Subject is in general good health

          -  If female, then postmenopausal

          -  If female, then not pregnant

          -  If male, must be surgically sterile or both he and the partner must use birth control

          -  Body Mass Index is 18 to 29, inclusive

        Criteria for HCV-infected Adults:

          -  Infected with HCV for at least 6 months as shown by either detectable HCV RNA or
             reactive antibody, or liver biopsy with pathology indicative of HCV infection, or
             disclosure of a risk factor

          -  Subject is infected with HCV genotype 1 with detectable HCV RNA of &gt; 50,000 IU/mL

        Exclusion Criteria:

        Criteria for Healthy Adults:

          -  If female, then pregnant or breast feeding

          -  Positive HAV-IgM, HBs-Ag, HCV Ab or HIV Ab

          -  Within 6 months of start of study, drug or alcohol abuse and use of nicotine products

          -  Alcohol intake within 48 hours prior to study drug administration

        Criteria for HCV-infected Adults:

          -  Need for prescription or over-the-counter medication

          -  Child Pugh score &gt; 5 or clinical evidence of cirrhosis

          -  No other cause for liver disease other than HCV infection

          -  ALT or AST &gt; 4 x ULN

          -  Creatinine &gt; ULN

          -  Clinically significant abnormal ECG

          -  HCV RNA levels above the level of assay quantification

          -  TSH values outside normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Global Medical Information</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Cohen, MD/Study Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

